09:23 AM EDT, 10/11/2024 (MT Newswires) -- Perspective Therapeutics ( CATX ) said Friday that initial results from a phase 1/2a study showed that its investigational radiopharmaceutical VMT01 is safe with no dose-limiting toxicities and leads to prolonged progression-free survival and tumor response in heavily pretreated patients with melanoma, allowing trials to expand.

The results were consistent with preclinical findings, which had led to a fast track designation from the US Food and Drug Administration, according to Perspective.

The company said it is planning to expand the study to explore a lower dose level, both as a single agent and in combination with the antibody nivolumab.

The nivolumab cohort is now active and open for enrollment, Perspective said.